UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) was the target of a significant increase in short interest in January. As of January 31st, there was short interest totalling 2,900 shares, an increase of 2,800.0% from the January 15th total of 100 shares. Based on an average daily volume of 77,100 shares, the short-interest ratio is currently 0.0 days.

UCB Price Performance

Shares of UCBJY stock opened at $98.94 on Thursday. The business’s fifty day simple moving average is $97.56 and its 200-day simple moving average is $93.51. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. UCB has a 12-month low of $49.55 and a 12-month high of $100.66.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.